Freezer Supplement to Hepatobiology and Toxicology COBRE
肝生物学和毒理学 COBRE 冷冻补充品
基本信息
- 批准号:10582198
- 负责人:
- 金额:$ 6.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-10 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAlcoholic Liver DiseasesAreaBasic ScienceBiomedical ResearchCenters of Research ExcellenceCirrhosisCollaborationsDevelopmentEnsureFreezingFundingGrantHepatitis BHepatitis CInjuryLaboratoriesLinkLiverLiver FailureLiver diseasesMentorsMetabolic syndromeMolecular TargetPharmaceutical PreparationsPhasePreventionPrimary carcinoma of the liver cellsProgram SustainabilityPublicationsResearchResearch InfrastructureResearch PersonnelResourcesTechnologyTherapeuticToxic Environmental SubstancesToxicant exposureToxicologyTranslational ResearchUniversitiescareer developmentclinical practicedrug induced liver injuryeducation researchexperienceliver injurymembermultidisciplinarynon-alcoholic fatty liver diseasenonalcoholic steatohepatitispersonalized medicinepreventprogramssuccess
项目摘要
The University of Louisville (UofL) Hepatobiology and Toxicology (H&T) COBRE is a unique thematic
center focused on liver research. The UofL H&T COBRE concentrates on the mechanisms and therapeutic
strategies for multiple forms of liver disease/injury, including: Non-alcoholic fatty liver disease/non-alcoholic
steatohepatitis—the most common liver disease in the US/worldwide, and is highly linked to the metabolic
syndrome; Alcoholic Liver Disease—a common problem among those who drink; Environmental Toxicant
Induced Liver Injury—an increasingly recognized problem, and Louisville has been a leader in this area;
Hepatitis B and C—important causes of cirrhosis and hepatocellular carcinoma worldwide; Personalized
Medicine—an increasingly important factor in medication efficacy, and most drugs are metabolized in the liver;
and Drug-Induced Liver Injury—the most common reason drugs are removed from the market and an
important cause of liver failure. This COBRE brings together experienced senior mentors/investigators and
promising junior investigators to perform cross-cutting research on the unique topics of Hepatobiology and
Toxicology. We address critical barriers in our understanding of the development/ progression of liver disease
and we define targets for prevention/treatment that could transform clinical practice.
Specific Aims of the Hepatobiology and Toxicology COBRE are to:
1. Expand and strengthen a thematically-focused program in Hepatobiology and Toxicology that helps build
and sustain the overall research infrastructure at UofL.
2. Expand and strengthen the multidisciplinary program in research education, mentoring and career
development in Hepatobiology and Toxicology, and systematically track and evaluate the progress.
3. Provide the necessary research resources and translational science/basic technologies to support state-of-
the-art research in Hepatobiology and Toxicology and to ensure sustainability of the program.
4. Discover new mechanisms/molecular targets and effective means for preventing and/or treating liver
diseases/toxicant exposures and communicate our findings to the public.
In summary, Phase I strengthened UofL’s biomedical research infrastructure through the establishment of
a thematic multidisciplinary center in hepatobiology and toxicology to enhance the ability of investigators to
compete for independent funding. In Phase I, we met or exceeded our metrics, including 1) four of our
investigators transitioning to independent research funding; 2) 91 mentee and 162 total publications; 3) new
renovated laboratory space; 4) numerous presentations; 5) establishing new collaborations; and 6) >$75
million in total new grant funding by H&T members. This Phase II proposal builds on our Phase I success,
extends and strengthens the scope of the program, and provides a roadmap for sustainability.
路易斯维尔大学(UofL)肝脏生物学和毒理学(H&T) COBRE是一个独特的专题
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CRAIG J. MCCLAIN其他文献
CRAIG J. MCCLAIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CRAIG J. MCCLAIN', 18)}}的其他基金
Inflammation Resolving Lipid Mediators: Novel Therapy for Alcohol AssociatedLiver Disease
消炎脂质介质:酒精相关性肝病的新疗法
- 批准号:
10590047 - 财政年份:2023
- 资助金额:
$ 6.8万 - 项目类别:
Administrative Supplement to Hepatobiology and Toxicology COBRE
肝生物学和毒理学 COBRE 行政增刊
- 批准号:
10399887 - 财政年份:2021
- 资助金额:
$ 6.8万 - 项目类别:
Alcoholic Hepatitis Network 3/9 University of Louisville
酒精性肝炎网络 3/9 路易斯维尔大学
- 批准号:
9752421 - 财政年份:2018
- 资助金额:
$ 6.8万 - 项目类别:
Alcoholic Hepatitis Network 3/9 University of Louisville
酒精性肝炎网络 3/9 路易斯维尔大学
- 批准号:
10434741 - 财政年份:2018
- 资助金额:
$ 6.8万 - 项目类别:
Alcoholic Hepatitis Network 3/9 University of Louisville
酒精性肝炎网络 3/9 路易斯维尔大学
- 批准号:
10202391 - 财政年份:2018
- 资助金额:
$ 6.8万 - 项目类别:
相似海外基金
Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver Diseases
揭示视黄酸受体β在酒精性肝病中的作用
- 批准号:
10019450 - 财政年份:2019
- 资助金额:
$ 6.8万 - 项目类别:
Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver Diseases
揭示视黄酸受体β在酒精性肝病中的作用
- 批准号:
9896234 - 财政年份:2019
- 资助金额:
$ 6.8万 - 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
- 批准号:
7990196 - 财政年份:2010
- 资助金额:
$ 6.8万 - 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
- 批准号:
8299173 - 财政年份:2010
- 资助金额:
$ 6.8万 - 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
- 批准号:
8102173 - 财政年份:2010
- 资助金额:
$ 6.8万 - 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
- 批准号:
8494464 - 财政年份:2010
- 资助金额:
$ 6.8万 - 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
- 批准号:
8693870 - 财政年份:2010
- 资助金额:
$ 6.8万 - 项目类别:
Screening of food components for the prevention of alcoholic liver diseases and their application
预防酒精性肝病的食品成分筛选及其应用
- 批准号:
21500783 - 财政年份:2009
- 资助金额:
$ 6.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Contribution of transforming growth factor-a to thr development of hepatic fibrosis in alcoholic liver diseases
转化生长因子-a对酒精性肝病肝纤维化发展的贡献
- 批准号:
09670560 - 财政年份:1997
- 资助金额:
$ 6.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Immunological mechanism on the generation of alcoholic liver diseases
酒精性肝病发生的免疫学机制
- 批准号:
03670349 - 财政年份:1991
- 资助金额:
$ 6.8万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)